Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study

OBJECTIVES: To evaluate efficacy and safety of the anti-interleukin-23p19 monoclonal antibody tildrakizumab in patients with psoriatic arthritis (PsA). METHODS: In this randomised, double-blind, placebo-controlled, phase IIb study, patients with active PsA were randomised 1:1:1:1:1 to tildrakizumab...

Descripción completa

Detalles Bibliográficos
Autores principales: Mease, Philip J, Chohan, Saima, Fructuoso, Ferran J Garcia, Luggen, Michael E, Rahman, Proton, Raychaudhuri, Siba P, Chou, Richard C, Mendelsohn, Alan M, Rozzo, Stephen J, Gottlieb, Alice
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Psoriatic Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8372392/
https://www.ncbi.nlm.nih.gov/pubmed/33985942
http://dx.doi.org/10.1136/annrheumdis-2020-219014

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8372392/
https://www.ncbi.nlm.nih.gov/pubmed/33985942
http://dx.doi.org/10.1136/annrheumdis-2020-219014

Ejemplares similares